Atai Life Sciences

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions.^{[1][2][3][4][5]} It was founded in 2018 and is headquartered in Berlin, Germany.^[1][5]

Atai Life Sciences

Trade name	NASDAQ: ATAI
Industry	Pharmaceutical; Psychedelic medicine
Founded	2018; 7 years ago (2018)
Headquarters	Berlin , Germany
Key people	Christian Angermayer, Florian Brand, Lars Christian Wilde, Srinivas Rao
Website	atai.com

The company's pharmaceutical candidates include dimethyltryptamine (DMT; VLS-01), (R)-midomafetamine ((R)-MDMA; EMP-01), and ibogaine (IBX-210, DMX-1002), as well as EGX-121 (a non-tryptamine new chemical entity), 5-MeO-DMT (BPL-003), psilocin (ELE-101), inidascamine (RL-007), deuterated mitragynine (KUR-101), EGX-A, EGX-B, deuterated etifoxine (GRX-917), and arketamine (PCN-101).^[4][3][6]

In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange.^[1][7] In January 2023, atai Life Science's leading drug candidate at the time, arketamine (PCN-101), failed to meet its primary endpoint in a clinical trial.^[1] Following that, the company laid off 30% of its staff.^[1]

Peter Thiel is a major investor in the company.^[1] atai Life Sciences has a 22.4% stake in Compass Pathways.^[1][5]